Comparative Pharmacology
Head-to-head clinical analysis: MAOLATE versus ZANAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAOLATE versus ZANAFLEX.
MAOLATE vs ZANAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from CNS, leading to decreased muscle tone and spasticity.
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
Initial: 2 mg orally every 6-8 hours as needed, up to 3 times daily. Maximum: 36 mg per day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life is approximately 2.5 hours in healthy adults; clinically, this short half-life necessitates multiple daily dosing for sustained effect and contributes to its use as needed for spasticity.
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Approximately 95% of a dose is eliminated via hepatic metabolism; renal excretion accounts for about 20% as unchanged drug and metabolites, with about 20% eliminated in feces.
Category C
Category C
Muscle Relaxant
Muscle Relaxant